[Chronic systolic heart failure - dosing recommendations at beginning and end of treatment].
As a multi-system disease, chronic heart failure requires a complex, multimodal therapy. Achieving maximum guideline adherence in (advanced) chronic heart failure can therefore become a challenge. The important decrease in morbidity and mortality seen lately largely depends on consequent and sometime tedious implementation of guideline targets. The present paper provides a comprehensive overview on medical therapeutic strategies with a particular focus of onset and discontinuation of drugs in patients with chronic systolic dysfunction.
Zugck
Christian
C
Abteilung für Innere Medizin III, Universitätsklinikum Heidelberg. Christian_Zugck@med.uni-heidelberg.de
Remppis
Andrew
A
Katus
Hugo A
HA
Frankenstein
Lutz
L
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000009:adverse effects; D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage / Q000009:adverse effects; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D002301:Cardiac Glycosides / Q000008:administration & dosage / Q000009:adverse effects; D002316:Cardiotonic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002908:Chronic Disease; D004232:Diuretics / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists / Q000008:administration & dosage / Q000009:adverse effects; D013599:Systole / Q000187:drug effects
D000319:Adrenergic beta-Antagonists; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D002301:Cardiac Glycosides; D002316:Cardiotonic Agents; D004232:Diuretics; D000451:Mineralocorticoid Receptor Antagonists